Theravance Biopharma Announces New Employment Inducement Awards
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Theravance Biopharma (TBPH) Announces Receipt of FDA Fast-Track Designation for TD-8954 With Enteral Feeding in Critically Ill Patients
August 6, 2015 8:06 AM EDTTheravance Biopharma (NASDAQ: TBPH) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to TD-8954 for short-term use with enteral feeding to achieve early nutritional adequacy in critically ill patients at high nutritional risk. TD-8954 is a selective 5-HT4 receptor agonist being evaluated for potential use in the treatment of gastrointestinal motility disorders, including enteral feeding intolerance (EFI). Importantly, there are currently no FDA-approved therapies for EFI, leaving the approximately one million Americans who suffer from the... More
